Biodesix (BDSX)
(Delayed Data from NSDQ)
$1.66 USD
+0.04 (2.47%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $1.67 +0.01 (0.60%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BDSX 1.66 +0.04(2.47%)
Will BDSX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BDSX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDSX
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
BDSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?
Other News for BDSX
Biodesix Named to Inc. Magazine’s 2024 “Best Workplaces”
Biodesix to Participate in Two Investor Conferences in June
Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting
Buy Rating Justified by Biodesix’s Market Leadership and Strong Growth Prospects
Biodesix initiated with bullish view at TD Cowen, here's why